Cas9

Cas9
Deposition authors: Nishimasu, H., Ishitani, R., Nureki, O.; Visualization autho · CC0 · source
Name	Cas9
Caption	CRISPR-associated protein 9
Organism	Various bacteria and archaea

Cas9 is a CRISPR-associated endonuclease widely used for RNA-guided DNA targeting. First characterized in Streptococcus pyogenes, Cas9 revolutionized genome engineering by enabling programmable double-strand breaks guided by a single-guide RNA, accelerating research across Broad Institute, MIT, Harvard University, Stanford University, Max Planck Society. Its development intersected with discoveries credited to researchers at University of California, Berkeley, University of Vienna, University of Alicante, University of Utah, and commercial entities such as Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences.

Overview

Cas9 functions as an RNA-guided DNA endonuclease in adaptive immune systems of bacteria and archaea, first linked to adaptive immunity alongside work at University of Copenhagen, University of California, San Diego, University of Michigan, Chinese Academy of Sciences, University of Tokyo, University of Oxford. Key early studies involved collaborations with groups at Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, National Institutes of Health, Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, Genentech, Illumina.

Structure and Mechanism

Cas9 adopts bilobed architecture with recognition (REC) and nuclease (NUC) lobes; structural insights came from crystallography and cryo-EM studies at institutions such as Riken, EMBL-EBI, Yale University, Columbia University, University of Pennsylvania. The enzyme binds a guide RNA derived from CRISPR arrays characterized by research at Pasteur Institute, Max Planck Institute for Infection Biology, Karolinska Institutet, McGill University, forming an R-loop with target DNA adjacent to a protospacer adjacent motif (PAM) discovered through analyses by groups at University of Copenhagen, Université Paris Diderot, University of Barcelona, University of Zurich, University of California, Davis. Catalytic residues within HNH and RuvC-like domains execute strand-specific cleavage, elucidated using techniques pioneered at Argonne National Laboratory, Lawrence Berkeley National Laboratory, Los Alamos National Laboratory, SLAC National Accelerator Laboratory, Brookhaven National Laboratory.

Biological Function and Natural Diversity

Cas9 variants occur across diverse taxa, with orthologs and paralogs identified in genomes sequenced by projects at Human Genome Project, 1000 Genomes Project, Genome Canada, Baylor College of Medicine Human Genome Sequencing Center, J. Craig Venter Institute. Comparative genomics by teams at Broad Institute, Sanger Institute, European Nucleotide Archive, GenBank, DDBJ revealed diversity in PAM specificity, size, and accessory factors including tracrRNA, anti-CRISPR proteins discovered by groups affiliated with University of Toronto, University of California, Berkeley, University of Washington, University of Pittsburgh, Johns Hopkins University. Natural roles span phage defense studies involving T4 bacteriophage, Lambda phage, P2 phage, and co-evolution research connected to labs at University of Cambridge, Princeton University, Duke University, University of Illinois Urbana-Champaign.

Applications in Genome Editing

Cas9 enabled rapid adoption of genome engineering in model systems maintained by Jackson Laboratory, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, Salk Institute, Scripps Research Institute. Applications include gene knockout, base editing modifications developed with collaborators at University of Toronto, University of California, San Francisco, Broad Institute, Howard Hughes Medical Institute and prime editing innovations involving teams at Broad Institute, MIT. Therapeutic development progressed in trials coordinated with Food and Drug Administration, European Medicines Agency, National Institutes of Health Clinical Center, and companies like Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics. Agricultural uses were pursued by researchers at Monsanto, DuPont Pioneer, Bayer, Syngenta and academic partners at Iowa State University, University of California, Davis, University of Illinois.

Delivery Methods and Engineering

Delivery strategies for Cas9 include viral vectors such as adeno-associated virus (AAV) and lentivirus studied by teams at University of Pennsylvania, Children's Hospital of Philadelphia, Massachusetts General Hospital, Cleveland Clinic; non-viral methods include lipid nanoparticles, electroporation, and ribonucleoprotein complexes advanced at Harvard Medical School, Stanford University, MIT Koch Institute, Wyss Institute, Salk Institute. Engineering efforts to alter PAM recognition, reduce off-targets, and modulate immunogenicity involved collaborations across Genentech, Novartis, Roche, Pfizer, GlaxoSmithKline and academic labs at Yale School of Medicine, University College London, Imperial College London.

Ethical, Safety, and Regulatory Considerations

Clinical and ethical debates around germline modification, somatic therapies, and dual-use research engaged stakeholders including World Health Organization, National Academy of Sciences, National Academy of Medicine, European Commission, United Nations Educational, Scientific and Cultural Organization, regulatory bodies like Food and Drug Administration, European Medicines Agency, and advisory panels assembled at National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute. High-profile events influencing policy included conferences at Asilomar Conference Grounds, proceedings involving Royal Society, Pontifical Academy of Sciences, and reports produced with contributions from Bill & Melinda Gates Foundation, Carnegie Endowment for International Peace, Center for Strategic and International Studies.

Category:Genome editing